Aging‐related matrix metallopeptidase 10 and osteopontin levels are associated with pathology, cognitive decline, and age at onset in Alzheimer's disease
Authors:
Open Access
- 22 April 2026
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71082
Abstract
INTRODUCTION: Aging is the strongest risk factor for Alzheimer's disease (AD) characterized by amyloid‐β (Aβ) plaques and tau tangles in the brain. We aim to compare biological aging‐related biomarkers among AD, non‐neurodegenerative control (NDC) and non‐AD neurodegenerative (Non‐AD) individuals to evaluate their clinical utility. METHODS: We included 137 participants (37 NDC, 67 AD, 33 Non‐AD) from the University College London (UCL) Dementia Research Centre and measured matrix metallopeptidase 10 (MMP‐10), osteopontin (OPN), neurofilament‐light, and glial fibrillary acidic protein in cerebrospinal fluid (CSF) in addition to Aβ/pTau and clinical parameters. RESULTS: Elevated MMP‐10 associated with poorer cognition and later onset specifically in AD, whereas elevated OPN associated with Aβ and tau pathology. MMP‐10 and OPN levels improved the differentiation of AD from NDC, and AD from Non‐AD, respectively. DISCUSSION: Our study provides evidence on potential clinical utility of CSF MMP‐10 and OPN in diagnosis and supports taking biological aging into consideration in AD research. Highlights: Elevated osteopontin and matrix metallopeptidase 10 (MMP‐10) levels in Alzheimer's disease (AD) cerebrospinal fluid. MMP‐10 levels are linked to age at onset and cognitive decline. Osteopontin levels are linked to AD pathologies in the cerebrospinal fluid. MMP‐10 levels improved discrimination of AD from non‐neurodegenerative controls. Osteopontin levels improved discrimination of AD from other neurodegenerative cases.Keywords
This publication has 44 references indexed in Scilit:
- Examining the influence of gender, education, social class and birth cohort on MMSE tracking over time: a population-based prospective cohort studyBMC Geriatrics, 2012
- Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive DeclineJournal of Alzheimer’s Disease, 2010
- Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive ImpairmentArchives of Neurology, 2007
- Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease BrainCurrent Alzheimer Research, 2007
- Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microgliaGlia, 2007
- Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in SituJournal of Biological Chemistry, 2006
- Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas.2003
- The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating DiseaseScience, 2001
- Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40)Journal of Neuroscience, 1996
- “Mini-mental state”Journal of Psychiatric Research, 1975